IZLETYDE
Live / Applied — Third extension granted (statement of use) (as of 04 Dec 2025)
What this means for you
Not registered yet, but its 11 Jul 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98080579
- Mark type
- Stylized text
- Filed
- 11 Jul 2023
- Published for opposition
- 07 May 2024
- Attorney of record
- Sarah Anne Keefe
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treating diabetes; medical treatments in the nature of anti-diabetic pharmaceuticals; stem cell-derived cell therapy composed of cells for medical or veterinary use
Owner
- Vertex Pharmaceuticals Incorporated, Boston, MA, US
- Vertex Pharmaceuticals Incorporated, Boston, MA, US
Prosecution history
- 05 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Dec 2025 — SOU EXTENSION 3 GRANTED
- 04 Dec 2025 — SOU EXTENSION 3 FILED
- 04 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 26 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Jun 2025 — SOU EXTENSION 2 GRANTED
- 25 Jun 2025 — SOU EXTENSION 2 FILED
- 25 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 09 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Dec 2024 — SOU EXTENSION 1 GRANTED
- 09 Dec 2024 — SOU EXTENSION 1 FILED
- 09 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 02 Jul 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 07 May 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 07 May 2024 — PUBLISHED FOR OPPOSITION